Clinical trials: Filovirus Disease
Filovirus Disease
Study of Filovirus Disease Morbi-mortality
Filoviruses, including Ebola and Marburg, cause hemorrhagic fevers associated with high mortality and still limited scientific literature, in particular for some rare species such as the Bundibugyo virus.
- Trial name
- TEMBO (NCT07821580)
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ebola Virus Disease
Multiple Treatments for Ebola Virus Disease (EVD)
The purpose of this study is to determine whether multiple therapeutic regimens are effective in the treatment of Ebola Virus Disease (EVD)
- Trial name
- NCT02380625
- Testing
- Azithromycin, Sunitinib and Erlotinib, Atorvastatin and Irbesartan
- Volunteers
- 150 people
- Sponsor
- Clinical Research Management, Inc.
Ebola Virus Disease
EBOla Post-Exposure Prophylaxis
EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.
- Trial name
- EBO-PEP (NCT06841614)
- Testing
- Ervebo, Inmazeb
- Where
- 4 sites in Democratic Republic of the Congo, Guinea and 2 more
- Volunteers
- 160 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hemorrhagic Fever, Ebola
Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea
This is an emergency, phase 2/3, open-label, non-randomized, clinical trial that will evaluate Convalescent Plasma (CP) added to standardized supportive care (SC) in patients with confirmed Ebola Virus Disease (EVD).
- Trial name
- Ebola-Tx (NCT02342171)
- Testing
- Convalescent Plasma
- Where
- Guinea
- Volunteers
- 606 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Acute Ebola Virus Disease
A Prospective, Open Label, Phase 1 Safety Study of Passive Immune Therapy During Acute Ebola Virus Disease Using Transfusion of INTERCEPT Plasma Prepared From Volunteer Donors Who Have Recovered From Ebola Virus Disease
The objective of this Phase 1 safety study is to provide access to the potential therapeutic benefit of EBOV convalescent plasma containing antibodies to EBOV.
- Trial name
- NCT02295501
- Testing
- INTERCEPT Plasma
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Cerus Corporation
Ebola Virus Disease
Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine
Interventional, single arm, open-label, non-randomized, phase IIIb study to accumulate additional data on safety and effectiveness of one dose of rVSVΔG-ZEBOV-GP against Ebola virus disease.
- Trial name
- NCT03161366
- Testing
- rVSVΔG-ZEBOV-GP
- Where
- 2 sites in Democratic Republic of the Congo, Uganda
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Epicentre
Ebola Virus Disease
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human MAb Ansuvimab As Therapeutic or for HR PEP
The human monoclonal antibody (mAb), ansuvimab (mAb114), will be provided to Ebola-infected patients as either a treatment or as PEP under an expanded access protocol.
- Trial name
- NCT05067166
- Testing
- Ansuvimab
- Sponsor
- Ridgeback Biotherapeutics, LP
Ebola Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - DRC
This study aims to validate the clinical performance of a newly developed isothermal nucleic acid amplification bioassay module for EBOV.
- Trial name
- NCT07688083
- Testing
- DECIPHER bioassay
- Volunteers
- 100 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Virus Disease
Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease
This study highlighted the possibility, even in epidemic settings, of providing advanced supportive care for patients with VMEs.
- Trial name
- EVISTA (NCT04815174)
- Testing
- Standard of Care
- Where
- Democratic Republic of the Congo
- Volunteers
- 711 people
- Sponsor
- Alliance for International Medical Action
Ebola Virus Disease
Efficacy of Favipiravir Against Ebola (JIKI)
There is no specific treatment for Ebola Virus Disease (EVD). Current EVD care are supportive, and includes intravenous or oral rehydration, nutrition, pain killers, treatment of coinfections with antibacterial and antimalarial…
- Trial name
- JIKI (NCT02329054)
- Testing
- Favipiravir
- Where
- 4 sites in Guinea
- Volunteers
- 126 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Sepsis Bacterial, Ebola Virus Disease
Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response
Despite access to experimental Ebola Virus Disease (EVD)-specific treatments, about 30% of patients still die in the Ebola Treatment Centers (ETC) in DRC.
- Conditions
- Sepsis Bacterial, Ebola Virus Disease, Bloodstream Infection
- Trial name
- Bact_EVD (NCT04250168)
- Where
- 2 sites in Democratic Republic of the Congo
- Volunteers
- 43 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola
African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola
This is a randomized, placebo-controlled, multi-site, double-blind trial of V920 (rVSVΔG-ZEBOV-GP) Ebola Virus vaccine candidate in subjects with HIV infection to be conducted in conformance with Good Clinical Practices.
- Trial name
- NCT03031912
- Testing
- V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine, Saline
- Where
- Canada
- Volunteers
- 251 people
- Sponsor
- Canadian Immunization Research Network
Ebola Hemorrhagic Fever, Lassa Hemorrhagic Fever
Clinical Validation of Isothermal Nucleic Acid Amplification Bioassays Modules - GUINEA
This study aim to validate the clinical performances of two newly developed isothermal nucleic acid amplification bioassays modules for EBOV and LASV.
- Trial name
- NCT07681752
- Testing
- FORTIFIEDx and DECIPHER bioassays
- Volunteers
- 150 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Ebola Hemorrhagic Fever, Bundibugyo Virus Disease
Study of Vaccines Against Bundibugyo Virus Disease in Contacts of Cases in the Democratic Republic of the Congo
Bundibugyo virus (BDBV) causes severe and often fatal outbreaks of Bundibugyo virus disease (BVD). No vaccine against BDBV is licensed.
- Trial name
- TUMAINI (NCT07842107)
- Testing
- Candidate BDBV vaccine, Active comparator
- Where
- Democratic Republic of the Congo
- Volunteers
- 3,620 people, healthy volunteers welcome
- Sponsor
- Jean-Pierre Van geertruyden
Ebola Virus Disease
Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo
The purpose of this study is the evaluation of the safety and immunogenicity of two candidate Ebola vaccines Ad26.ZEBOV and MVA-BN-Filo, in a 2-dose heterologous regimen.
- Trial name
- EBOVAC-Salone (NCT02509494)
- Testing
- Ad26.ZEBOV, MVA-BN-Filo, MenACWY
- Where
- Sierra Leone
- Volunteers
- 1,023 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.